8-K current report · filed Aug 4, 2026

Larimar Therapeutics, Inc. (LRMR) 8-K Current Report: August 4, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 2.02LRMR overview

Short answer

Larimar Therapeutics, Inc. (LRMR) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Second-quarter 2026 financial results and operational highlights announced for period ended June 30, 2026.

Larimar Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Second-quarter 2026 financial results and operational highlights announced for period ended June 30, 2026
  • Investors should review Exhibit 99.1 for detailed financial figures and development updates

Item 8.01 · Other Events

  • Updated investor presentation posted August 4, 2026, signaling refreshed corporate and pipeline messaging
  • Exhibit 99.2 contains the substantive presentation for investors and analysts
  • Ongoing use in meetings may influence market expectations around Larimar’s development programs

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net loss $32.8M, or $0.30/share, versus $26.2M, reflecting accelerating development and commercialization spending
  • Cash, equivalents and marketable securities $156.3M at June 30, supporting runway into Q3 2027 without near-term financing indicated
  • Rolling BLA underway after FDA alignment, with completion targeted for 2H 2026 and accelerated approval dependent on regulatory review
  • Phase 3 confirmatory dosing expected Q3 2026, a key validation milestone for nomlabofusp’s potential approval pathway
  • Safety and efficacy signals remain supportive, though 10 anaphylaxis cases caused study discontinuations among 43 participants

Item EX-99.2 · Exhibit EX-99.2

  • Nomlabofusp’s first rolling BLA module was submitted in June 2026, with remaining modules targeted for 2H 2026
  • FDA indicated the existing data package appears sufficient for accelerated-approval review using FXN as a novel surrogate endpoint
  • Global Phase 3 trial expected to dose its first patient in Q3 2026, targeting 100 to 150 ambulatory participants
  • $156.3 million cash and investments as of June 30, 2026, projected to fund operations into Q3 2027
  • Potential U.S. launch targeted for mid-2027, contingent on approval, with rare pediatric disease priority review voucher eligibility expected

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Larimar Therapeutics, Inc. 8-K filings

Get the next LRMR 8-K as it lands

Follow LRMR for push alerts, or ask the research agent what this filing means.